Observational studyMedicine2018
Prognostic factors to survival of patients with chondroblastic osteosarcoma.
Observational study in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Chondroblastic Subtype Is Associated with Higher Rates of Local Recurrence in Skeletal Osteosarcoma.Journal of clinical medicine · 2025Article
- Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications.Biology · 2025Review
- Development and validation of a predictive score for chemoresistance in high-grade osteosarcoma at baseline.Frontiers in medicine · 2025Article
- Mapping the Single-Cell Differentiation Landscape of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Article
- Prognostic analysis and clinical characteristics of osteosarcoma and Ewing sarcoma of the rib, sternum, and clavicle: a SEER-based study.The Journal of international medical research · 2023Article
- Establishment and validation of systematic prognostic nomograms in patients over 60 years of age with osteosarcoma: A multicenter external verification study.Cancer medicine · 2023Article
- Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.Joint diseases and related surgery · 2023Article
- Analysis of Clinical Manifestations and Prognostic Factors Affecting Osteosarcoma.Disease markers · 2022Article
- Contemporary management of advanced midface malignancy in the age of Instagram - a parallel surgical and patient's perspective.British dental journal · 2021Article
- Downregulation of miR-588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma.Experimental and therapeutic medicine · 2021Article
- Development and Validation of Prognostic Nomograms for Elderly Patients with Osteosarcoma.International journal of general medicine · 2021Article
- Clinical and Oncological Outcome of Chondroblastic Osteosarcoma: A Single Institutional Experience.Indian journal of orthopaedics · 2020Article
- A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.Scientific reports · 2020Article
- Primary extradural tumors of the spinal column: A comprehensive treatment guide for the spine surgeon based on the 5Journal of craniovertebral junction & spineReview
- Prognostic Factors in Patients With Osteosarcoma With the Surveillance, Epidemiology, and End Results Database.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed to reveal the changes in survival rates and prognostic factors to survival of chondroblastic osteosarcoma (COS).Patients from the Surveillance, Epidemiology, and End Results (SEER) database were retrieved. Kaplan-Meier survival analysis and Cox proportional hazard model were used during analysis.There were significant differences on overall survival between subtypes of osteosarcoma (P < .001*). Overall survival of COS did not change significantly during last forty years (P = .610), and cancer-specific survival increased to a plateau in 1980s and then remained stable (P = .058). Younger onset age, patients of white race, well and moderately differentiated tumors, and surgery independently predicted better overall (Hazard ratio [HR]: 1.034, P < .001*; HR: 0.538, P = .004*; HR: 0.240, P = .020* and HR: 0.350, P < .001*, respectively) and cancer-specific (HR: 1.031, P = .002*; HR: 0.592, P = .036*; HR: 0.098, P = .027* and HR: 0.253, P < .001*, respectively) survival. Metastasis at diagnosis independently predicted worse overall (HR: 3.108, P < .001*) and cancer-specific (HR: 4.26, P < .001*) survival compared to no metastasis.Younger onset age, white race, well and moderately differentiated tumors, no metastasis at diagnosis and surgical resection can independently predict better overall and cancer-specific survival of COS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.